Biomarker and IVD pipeline
Scailyte’s clinical focus is to develop precision diagnostic applications for multimodal single-cell data in oncology and women’s health by identifying biomarkers that outperform the current standard of care.
Establishing a precision diagnostics portfolio
Cutaneous T-cell lymphoma
First disease biomarker clinically validated:
Our trained AI demonstrated unprecedented accuracy in a blinded study
Cutaneous T cell lymphoma (CTCL) is a rare and severe skin cancer. In its initial stages CTCL shares similar symptoms to highly prevalent skin conditions such as atopic dermatitis (AD). Currently there is a lack of a definitive diagnostic test for CTCLs which means the disease is typically identified in advanced stages, once the patient’s immune system is compromised, or worse: altogether misdiagnosed. For the most aggressive form of CTCL, Sezary Syndrome, the 5 year survival rate is between 20–27%.
Scailyte is courageous. We’ve stepped up to the challenge by developing a precise, predictive and trustworthy diagnostic test.
Using our proprietary AI driven cell analytics pipeline, we identified CTCL- specific biomarkers that accurately diagnose CTCL with >90% specificity and sensitivity.
This powerful diagnostic test will enable early intervention, improve patient’s quality of life, reduce treatment costs and most importantly, save lives.